Brokerages Anticipate Cambrex Co. (CBM) to Announce $0.53 EPS

Share on StockTwits

Analysts expect that Cambrex Co. (NYSE:CBM) will report earnings of $0.53 per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Cambrex’s earnings. The lowest EPS estimate is $0.47 and the highest is $0.63. Cambrex reported earnings of $0.37 per share in the same quarter last year, which would suggest a positive year over year growth rate of 43.2%. The firm is scheduled to announce its next earnings results on Thursday, May 2nd.

On average, analysts expect that Cambrex will report full-year earnings of $1.95 per share for the current financial year, with EPS estimates ranging from $1.87 to $1.99. For the next fiscal year, analysts forecast that the business will report earnings of $2.10 per share, with EPS estimates ranging from $1.92 to $2.45. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Cambrex.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Wednesday, February 13th. The biotechnology company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.12. Cambrex had a net margin of 17.37% and a return on equity of 14.74%. The company had revenue of $212.30 million during the quarter, compared to analysts’ expectations of $182.49 million. During the same quarter in the prior year, the company earned $1.26 EPS. Cambrex’s revenue was up 16.5% compared to the same quarter last year.

CBM has been the subject of several research reports. TheStreet cut shares of Cambrex from a “b” rating to a “c+” rating in a research note on Monday, December 3rd. ValuEngine cut shares of Cambrex from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 26th. Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $51.00 price target for the company in a research note on Wednesday, January 9th. Finally, Craig Hallum dropped their price target on shares of Cambrex from $71.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, February 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $48.75.

NYSE CBM traded down $0.10 during trading hours on Tuesday, hitting $39.35. 5,065 shares of the company’s stock traded hands, compared to its average volume of 430,901. Cambrex has a 52-week low of $33.80 and a 52-week high of $69.43. The stock has a market cap of $1.33 billion, a PE ratio of 14.19, a P/E/G ratio of 3.47 and a beta of 2.42. The company has a current ratio of 3.93, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46.

In other news, COO Shawn Cavanagh sold 6,769 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $37.60, for a total value of $254,514.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Gregory Sargen sold 5,802 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $37.45, for a total transaction of $217,284.90. The disclosure for this sale can be found here. Corporate insiders own 1.41% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Teachers Advisors LLC lifted its holdings in shares of Cambrex by 19.8% in the 3rd quarter. Teachers Advisors LLC now owns 73,543 shares of the biotechnology company’s stock worth $5,030,000 after acquiring an additional 12,166 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Cambrex in the 3rd quarter worth approximately $321,000. MetLife Investment Advisors LLC lifted its holdings in Cambrex by 56.3% during the 3rd quarter. MetLife Investment Advisors LLC now owns 23,719 shares of the biotechnology company’s stock worth $1,622,000 after buying an additional 8,539 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its holdings in Cambrex by 10.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 253,109 shares of the biotechnology company’s stock worth $9,557,000 after buying an additional 23,800 shares in the last quarter. Finally, Dupont Capital Management Corp lifted its holdings in Cambrex by 16.9% during the 4th quarter. Dupont Capital Management Corp now owns 34,139 shares of the biotechnology company’s stock worth $1,289,000 after buying an additional 4,923 shares in the last quarter.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Read More: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.